Palatini P - Search Results

1

Stereospecific disposition of flunoxaprofen enantiomers in human beings.

Palatini P, Montanari G, Perosa A, Forgione A, Pedrazzini S, Furlanut M. Palatini P, et al. Int J Clin Pharmacol Res. 1988;8(3):161-7. Int J Clin Pharmacol Res. 1988. PMID: 3403103

2

Absorption and disposition kinetics of flunoxaprofen and benoxaprofen in healthy volunteers.

Furlanut M, Montanari G, Perosa A, Velussi C, Forgione A, Palatini P. Furlanut M, et al. Among authors: palatini p. Int J Clin Pharmacol Res. 1985;5(3):165-70. Int J Clin Pharmacol Res. 1985. PMID: 4018949

3

Effect of age on single- and multiple-dose pharmacokinetics of erythromycin.

Miglioli PA, Pivetta P, Strazzabosco M, Orlando R, Okolicsanyi L, Palatini P. Miglioli PA, et al. Among authors: palatini p. Eur J Clin Pharmacol. 1990;39(2):161-4. doi: 10.1007/BF00280051. Eur J Clin Pharmacol. 1990. PMID: 2253666

4

Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.

Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, Gallimberti L, Gessa GL, Ferrara SD. Palatini P, et al. Eur J Clin Pharmacol. 1993;45(4):353-6. doi: 10.1007/BF00265954. Eur J Clin Pharmacol. 1993. PMID: 8299669

5

Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.

Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, Padrini R, Palatini P. Ferrara SD, et al. Among authors: palatini p. Eur J Clin Pharmacol. 1996;50(4):305-10. doi: 10.1007/s002280050113. Eur J Clin Pharmacol. 1996. PMID: 8803524

6

Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.

Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Orlando R, et al. Among authors: palatini p. Clin Pharmacol Ther. 2004 Jan;75(1):80-8. doi: 10.1016/j.clpt.2003.09.007. Clin Pharmacol Ther. 2004. PMID: 14749694 Clinical Trial.

7

Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.

Orlando R, Piccoli P, De Martin S, Padrini R, Palatini P. Orlando R, et al. Among authors: palatini p. Br J Clin Pharmacol. 2003 Jan;55(1):86-93. doi: 10.1046/j.1365-2125.2003.01718.x. Br J Clin Pharmacol. 2003. PMID: 12534644 Free PMC article. Clinical Trial.

8

Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.

De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P. De Martin S, et al. Among authors: palatini p. Clin Pharmacol Ther. 2006 Dec;80(6):597-606. doi: 10.1016/j.clpt.2006.08.020. Clin Pharmacol Ther. 2006. PMID: 17178261 Clinical Trial.

9

Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.

Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P. Orlando R, et al. Among authors: palatini p. Clin Pharmacol Ther. 2006 May;79(5):489-99. doi: 10.1016/j.clpt.2006.01.012. Clin Pharmacol Ther. 2006. PMID: 16678550 Clinical Trial.

10

The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis.

Orlando R, Benvenuti C, Mazzo M, Palatini P. Orlando R, et al. Among authors: palatini p. Br J Clin Pharmacol. 1995 Apr;39(4):445-8. doi: 10.1111/j.1365-2125.1995.tb04475.x. Br J Clin Pharmacol. 1995. PMID: 7640153 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

587 results

Search Page

Filters